$15.97
+6.9%Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Wall Street analysts project that SDGR stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 18.00, with estimates ranging from a low of 18.00 to a high of 18.00.
The consensus 1-year price target stands at 18.00, with estimates ranging from a low of 18.00 to a high of 18.00.
Moderate upside. Analysts expect positive returns but with limited margin of safety. Consider entry timing.
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Solid growth trajectory indicates healthy business performance and competitive positioning.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Moderate uncertainty in forecasts—typical for companies with evolving business models.
Generally favorable outlook with reasonable growth prospects and analyst support.
Moderate growth expected, typical for mature businesses with stable market positions.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
High forecast uncertainty: Wide estimate range indicates analysts struggling to predict outcomes—suggests elevated risk and potential volatility.
Moderate growth expected, typical for mature businesses with stable market positions.
Limited coverage may indicate reduced institutional interest or information availability.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
High forecast uncertainty: Wide estimate range indicates analysts struggling to predict outcomes—suggests elevated risk and potential volatility.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Moderate uncertainty in forecasts—typical for companies with evolving business models.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Declining estimates with wide disagreement: Analysts projecting contraction without consensus signals significant business uncertainty—exercise caution.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Moderate uncertainty in forecasts—typical for companies with evolving business models.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Declining estimates with wide disagreement: Analysts projecting contraction without consensus signals significant business uncertainty—exercise caution.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Moderate uncertainty in forecasts—typical for companies with evolving business models.
Generally favorable outlook with reasonable growth prospects and analyst support.
During the last 12 months, insiders have sold $1.30M worth of SDGR shares, with no buying activity reported.
0
0.00
87.5K
1.07M
-1.1M
-$1.07M
0
0.00
14.7K
192.78K
-193K
-$193K
0
0.00
1.4K
29.39K
-29K
-$29K
0
0.00
0
0.00
+0
+$0
No buying activity
Farid Ramy
Director, Officer: President & Ceo
$1.10M
Abel Robert Lorne
Officer: See Remarks
$33K
Jain Rachit
Officer: Evp & Cfo
$32K
Dugan Margaret
Officer: Chief Medical Officer
$29K
Lorton Kenneth Patrick
Officer: Evp, Cto & Coo, Software
$28K
Strong bearish signal with $1.30M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
Continue your SDGR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.